Skip to main content
PERCHERON THERAPEUTICS LIMITED logo

PERCHERON THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PER ISIN · AU0000317281 LEI · 984500FF63A961E0K787 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,206 across all filing types
Latest filing 2022-04-28 Director's Dealing
Country AU Australia
Listing ASX PER

About PERCHERON THERAPEUTICS LIMITED

https://percherontx.com

Percheron Therapeutics Limited is a clinical-stage company focused on the development of novel antisense pharmaceuticals for rare diseases. The company's lead program, ATL1102, is an antisense oligonucleotide targeting the CD49d receptor, a subunit of the VLA-4 integrin. This therapeutic candidate is primarily being developed for the treatment of Duchenne muscular dystrophy (DMD), where it aims to reduce inflammation and muscle damage by modulating the immune system's response. Formerly known as Antisense Therapeutics, the firm utilizes its proprietary antisense technology platform to create targeted therapies that inhibit the production of proteins associated with disease progression. The company's research and development efforts are centered on addressing significant unmet medical needs through precision genetic medicine.

Recent filings

Filing Released Lang Actions
Change of Director's Interest Notice (CG,MD) 4 pages 297.7KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by company directors, including number of shares and options held before and after the change, nature of the change, and dates. The document is a formal notification of personal share transactions by company directors. There is no financial performance data, earnings information, or management discussion. The content matches the definition of Director's Dealing filings, which report personal share transactions by company directors and executives (insider trades). The document length is 7875 characters, sufficient to contain detailed transaction data. Therefore, the correct classification is DIRS (Director's Dealing).
2022-04-28 English
Bonus Options Issue - Letter to Shareholders 1 page
Share Issue/Capital Change Classification · 95% confidence The document is a letter dated 29 April 2022 from the Company Secretary of Antisense Therapeutics Limited to shareholders. It confirms the issuance of new options (bonus issue) to eligible shareholders on the basis of one option for every twenty shares held on the record date. The letter explains the terms of the options, including exercise price, expiry date, and non-quotation on the ASX. It also references a Prospectus lodged with ASIC on 12 April 2022 and provides a link to download it. The document is an announcement to shareholders about the issuance of new options as part of a capital change event. It does not contain financial statements or detailed financial analysis but rather informs shareholders about the share option issuance. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length is short (2070 characters), and it is not merely announcing a report but is itself the communication of the capital change event.
2022-04-28 English
Quarterly Activities/Appendix 4C Cash Flow Report 8 pages 363.7KB
Interim / Quarterly Report Classification · 100% confidence The document is an ASX announcement dated 28 April 2022, titled 'Quarterly Activities Report & Appendix 4C'. It provides a quarterly update on company activities, including research progress, collaborations, and financial cash flow data for the quarter ended 31 March 2022. The inclusion of the Appendix 4C, which is a quarterly cash flow report required by ASX Listing Rule 4.7B, confirms this is a quarterly report. The document contains substantive financial data such as cash flows from operating, investing, and financing activities, and detailed operational updates. It is not merely an announcement of a report but the report itself. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q3 2022
2022-04-27 English
Notification regarding unquoted securities - ANP 5 pages 26.5KB
Capital/Financing Update Classification · 95% confidence The document is titled 'Notification of Issue, Conversion or Payment up of Unquoted Equity Securities' and details the issuance of unquoted securities by Antisense Therapeutics Limited. It includes specifics such as the number of securities issued, issue dates, and references to previous announcements (Appendix 3B). The content focuses on the issuance of securities, not on financial results, management changes, or other report types. The document is about a capital transaction involving securities issuance, which aligns with the category for capital or financing updates. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (6143 characters) supports it being a full announcement rather than a brief notice or report publication announcement.
2022-04-27 English
Receipt of R&D Tax Incentive Payment 1 page 94.0KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 14 April 2022 regarding the receipt of an R&D Tax Incentive payment from the Australian Taxation Office for the financial year ending 30 June 2021. The content is brief, only 2189 characters, and primarily informs about the receipt of a tax refund related to R&D activities. There are no financial statements, detailed financial analysis, or comprehensive report content. It is an announcement of a specific financial event (receipt of a tax incentive payment), not a full financial report or detailed management discussion. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories.
2022-04-13 English
Bonus Option Offer 3 pages 135.6KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 12 April 2022 regarding a Bonus Option Offer by Antisense Therapeutics Limited. It details the terms of the option offer, key dates, and the intended use of funds raised from exercising the options. It also provides updates on clinical trial progress and regulatory feedback from the US FDA. The document is primarily about a capital raising activity through issuing new options to shareholders and does not contain financial statements or detailed financial performance data. It is not a full financial report, earnings release, or management discussion. The focus on the option offer and fundraising classifies this as a Capital/Financing Update.
2022-04-11 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.